Sonnet BioTherapeutics Holdings, Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a new patent related to its modified form of Interleukin-18 ...

This therapy treats a rare paediatric condition, primary monogenic interleukin-18 (IL-18)-driven hyperinflammatory syndrome, which can lead to rapid multiple organ failure and mortality if not ...